FORM PTO-1390 (REV. 01-2003) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTORNEY'S DOCKET NUMBER CL001362-US TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5 DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/US03/06667 05 March 2002 05 March 2003 TITLE OF INVENTION Isolated Human Transporter Proteins, Nucleic Acid Molecules Encoding Human Transporter Proteins, and Uses Thereof APPLICANT(S) FOR DO/EO/US Qi, Rong, et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. The US has been elected (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. \square A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification.

A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.

A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

A second copy of the published international application under 35 U.S.C. 154(d)(4).

16.

17. 🗹

19.

20.

A power of attorney and/or change of address letter.

Other items or information:

U.S. APPLICATION OF THOO 1. 5237 (FR 63) 5 1 7 INTERNATIONAL APPLICATION NO. TO Be Assigned 5 1 Po T/US03/06667					ATTORNEY'S DOCKET NUMBER CL001362-US				
21. The following fees are submitted:						CALCULATIONS PTO USE ONLY			
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):									
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO									
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO\$900.00									
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO									
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$720.00									
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00									
ENTER APPROPRIATE BASIC FEE AMOUNT =						50.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months									
from the earliest claimed priority date (37 CFR 1.492(e)).						· · · · · · · · · · · · · · · · · · ·			
CLAIMS	NUMBER FIL		NUMBER EXTRA	RATE	\$				
Total claims	23 - 20		3	x \$18.00	\$	54.00			
Independent claims	6 -3		3	x \$84.00	\$_2 \$	52.00			
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$280.00						.056.00			
TOTAL OF ABOVE CALCULATIONS = Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.						,030.00	,		
SUBTOTAL =					\$				
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					\$				
TOTAL NATIONAL FEE =					\$ 1	,056.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					\$				
TOTAL FEES ENCLOSED =						056.00			
						ount to be refunded:	\$		
						charged:	\$		
 a. A check in the amount of \$ to cover the above fees is enclosed. b. Please charge my Deposit Account No. 50-0970 in the amount of \$ 1,056.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0970 . A duplicate copy of this sheet is enclosed. d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. 									
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.									
SEND ALL CORRESPONDENCE TO:									
CELERA GENOMICS SIGNATU						JRE C			
45 West Gude Drive C2-21						n-Hoffman			
Rockville, Maryland 20850 NAME									
47,98						3			
ł							ATION NUMBER		



10/506513

DT09 Rec'd PCT/PTO 0 3 SEP 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: QI, Rong, et al.

Art Unit:

Serial No. (to be assigned)

Examiner:

Filed: September 3, 2004

Atty. Docket: CL001362-US

For: ISOLATED HUMAN TRANSPORTER PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN TRANSPORTER PROTEINS, AND USES THEREOF

Submission Of Sequence Listing Under 37 CFR § 1.821(a)

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. § 1.821(a), applicants submit the Sequence Listing, including the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

It is respectfully believed that this application complies with the Sequence Listing requirements and is now in condition for processing.

Respectfully submitted,

Date: September 3, 2004

Lin Sun-Hoffman, Ph.D., Reg No. 47,983

Celera Genomics
45 West Gude Drive, C1-316
Rockville, MD 20850

Tel: 240-453-3067 Fax: 240-453-3084